Pharvaris

Close up shot of the target from a dart game
Biotech

Pharvaris ph. 3 win builds case for HAE drug sitting with FDA

Pharvaris’ deucrictibant has tasted success in a second phase 3 study, strengthening the case for the therapy to treat hereditary angioedema patients.
James Waldron Sep 8, 2026 10:10am
An arrow incrementally going up stairs before pointing straight up Blue background

Pharvaris clocks a pivotal win in race for rapid HAE relief

Dec 3, 2025 9:10am
Go sign green light

FDA lifts remaining hold on Pharvaris’ HAE drug

Jan 22, 2024 7:32am
finch canary cage free bird release

Pharvaris oral hereditary angioedema med cuts attacks in phase 2

Dec 6, 2023 10:18am
FDA

Pharvaris runs tox test to reverse clinical hold for HAE asset

Jan 9, 2023 10:42am
parachutes

Ex-Pfizer R&D head Abraham joins Vividion—Chutes & Ladders

Feb 14, 2020 9:30am